Back

Roland R Griffiths

Roland R Griffiths is a psychopharmacologist at the Johns Hopkins School of Medicine.[12]He specializes in psychiatry and behavioral biology.[32]He is a member of Departments of Psychiatry and Neurosciences.[4]

Roland Griffiths, Ph.D., is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine.[5]He is the principal investigator of the Johns Hopkins Psilocybin Project.[5]In 2009, he conducted the first major study of drugs and spirituality since the 1970s and has launched several more since.[6]His main line of work has been studying the subjective and behavioral effects of mood-altering drugs, and has written over 360 journal articles and book chapters –e.g.[7]He ended up switching his research program to the scientific study of psilocybin and went on to publish a landmark double-blind clinical study of the psychological effects of the compound in 2006.[8]Currently, his team is also testing psilocybin for its effects on treatment-resistant depression and smoking cessation, and examining its long-term effects on meditators and religious leaders.[9]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Roland R Griffiths on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Johns Hopkins School of Medicine

Employer

  • 1

    Event

  • 676

    Mentions

  • 226

    Docs

Recent events

Magic Mushroom Hallucinogen Boosts Cancer Patients' Mental Health

Cancer patients often experience mental anguish and stress, but a single dose of a hallucinogen found in psychedelic mushrooms, along with psychological counseling, improved their mindset, two studies said Thursday. A similar study by researchers at Johns Hopkins University involving 51 patients also showed big improvements in anxiety and depression. "The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions," said Roland Griffiths, professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine in a statement. Among those who took part in the Johns Hopkins study, 67 percent said the experience was among the top five meaningful experiences in their lives and 83 percent reported increases in their well-being.[1011]

2016-12-02

Event Date

References